Results 261 to 270 of about 749,800 (313)
Some of the next articles are maybe not open access.
Vaccine, 2008
Several recombinant vaccines expressing the rabies virus glycoprotein have been developed, particularly for the oral vaccination of wildlife. While these vaccines induce protective immunity in some animal species such as foxes, they are less effective in others.
Ziguo, Yuan +6 more
openaire +2 more sources
Several recombinant vaccines expressing the rabies virus glycoprotein have been developed, particularly for the oral vaccination of wildlife. While these vaccines induce protective immunity in some animal species such as foxes, they are less effective in others.
Ziguo, Yuan +6 more
openaire +2 more sources
Safety of secukinumab in hepatitis B virus
Journal of the European Academy of Dermatology and Venereology, 2017The usage of TNF antagonists in patients with hepatitis B virus (HBV) can result in viral reactivation and potential liver failure. However, little is known about the risk of viral reactivation with the newer IL-17 antagonists. We report a patient with seropositive hepatitis B, ankylosing spondylitis, and disabling palmar plantar psoriasis treated ...
S.L. Bevans, T.T. Mayo, B.E. Elewski
openaire +1 more source
Postlicensure safety evaluation of human papilloma virus vaccines
International Journal of Risk & Safety in Medicine, 2011Objective: A summary of postlicensure safety information of HPV vaccines from three sources: VigiBase, the global database of WHO's Programme for International Drug Monitoring, the VAERS report on Gardasil® and the RIVM report on Cervarix®. Method: all AEFI from the three sources were recalculated to a percentage of all AEFI reported for each of the ...
openaire +2 more sources
West Nile virus and blood product safety in Germany
Journal of Medical Virology, 2008AbstractWest Nile Virus (WNV) is a mosquito‐transmitted flavivirus, widely distributed throughout Africa, Asia and the Middle East. WNV may cause epidemics of human meningoencephalitis. The unexpected emergence of WNV (New York, 1999) and its rapid spread throughout North America during the following years caused a number of blood transfusion‐ and ...
Christa, Pfleiderer +9 more
openaire +2 more sources
Efficacy and safety of a feline immunodeficiency virus vaccine
Animal Health Research Reviews, 2004AbstractFel-O-Vax FIV is an inactivated virus vaccine designed as an aid in the prevention of infection of cats, 8 weeks or older, by feline immunodeficiency virus (FIV). It contains two genetically distinct FIV strains. The efficacy of this vaccine was demonstrated in a vaccination–challenge study designed to meet various regulatory requirements for ...
Chengjin, Huang +5 more
openaire +2 more sources
Occupational safety and health protections against Ebola virus disease
American Journal of Industrial Medicine, 2015Even as the Ebola epidemic is finally showing signs of remitting, controversy continues regarding the modes of disease transmission, the understanding of which necessarily dictates methods of prevention. The initial public health response to the epidemic was based on assumptions formed during previous outbreaks, and in the belief that transmission was ...
Knut, Ringen +5 more
openaire +2 more sources
VIRUS SAFETY OF SOLVENT/DETERGENT-TREATED ANTIHAEMOPHILIC FACTOR CONCENTRATE
The Lancet, 1988The safety of an antihaemophilic factor concentrate treated with the organic solvent tri-(n-butyl)phosphate and sodium cholate (factor VIII-SD) was assessed for transmission of non-A, non-B (NANB) hepatitis and human immunodeficiency virus (HIV). Patients enrolled in the study had no previous exposure to blood products made from plasma pools, although ...
M S, Horowitz +3 more
openaire +2 more sources
H5N1 influenza virus and the safety of plasma products
Transfusion, 2007BACKGROUND: The ever‐increasing number of human H5N1 influenza virus infections may enable these viruses to acquire the ability to spread effectively among humans and potentially to cause a pandemic. Recently, more systemic virus dissemination was reported during H5N1 virus infection of humans, resulting in significant virus concentrations also in the ...
T R, Kreil +6 more
openaire +2 more sources
Clinical evaluation of virus safety and inhibitor incidence
Blood Coagulation & Fibrinolysis, 1995The basic statistical issue in pharmacovigilance is to claim, with reasonable certainty, that the incidence of an event of interest in a population of subjects is less than a certain value. How many subjects and events must be observed before such a claim can be made?
M, Buyse, J L, Poplavsky
openaire +2 more sources
Monoclonal Antibody Production: Minimising Virus Safety Issues
2004Therapeutic compounds derived from biological fluids or tissues, or biopharmaceutical products, pose a number of problems for manufacturers and regulatory authorities when considering virus safety. Previous experience has demonstrated the potential for transmission of infectious viruses from a small number of biopharmaceutical products.
John Bray, Malcolm K. Brattle
openaire +1 more source